VISKEN
LOE ApproachingNDAORALTABLET
Approved
Sep 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VISKEN is an oral tablet small-molecule NDA approved in 1982 by Novartis. The generic name and mechanism of action are not specified in available data, limiting characterization of its therapeutic mechanism. It is indicated for oral use as a tablet formulation.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity); expect mature brand team focused on maximizing remaining patent life and managing generic transition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate a mature product with stable, smaller team requiring no active recruitment. Working on VISKEN offers experience managing established medications through LOE transition—valuable for career progression into lifecycle management and generic strategy roles.
Brand ManagerField Sales
Worked on VISKEN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.